Systematic literature review reveals conflicts of interest affecting testimony in advisory committees, suggesting improved disclosure practices.
COIs remain prevalent in FDA advisory committees, particularly among public speakers, where they are strongly associated with favorable testimony. These findings underscore the need for stronger and more consistent COI disclosure and management policies that include both committee members and public speakers to protect decision-making integrity.
No takes yet. Share an insight, caveat, or question.
Gentilini et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: